HAS Healthcare Advanced Synthesis SA is a full-service CDMO headquartered in Biasca, Switzerland, serving pharmaceutical and biotechnology clients from clinical development through to commercial supply. Founded in 1984, the company focuses on creating tailored solutions for complex chemical synthesis and manufacturing challenges, with an emphasis on high-value active pharmaceutical ingredients (APIs), highly potent APIs (HPAPIs) and anticancer compounds. Its facilities operate under current Good Manufacturing Practice (cGMP) standards and are routinely inspected by SwissMedic, the US Food and Drug Administration and other global regulators. HAS Healthcare Advanced Synthesis brings together technical expertise, regulatory support and scalable production capabilities to support clients’ needs across diverse therapeutic areas.

Key products and services

• Development and manufacturing of Active Pharmaceutical Ingredients (APIs) from early clinical to commercial scale.
• Production of High Potency APIs (HPAPIs) with specialised containment and process expertise.
• Synthesis and supply of anticancer compounds and oncology-related intermediates.
• cGMP contract development and manufacturing services tailored to client requirements.
• Support for analytical, regulatory and quality requirements linked to drug substance production.

HAS Healthcare Advanced Synthesis SA maintains a strategic focus on precision, compliance and client collaboration. The company’s integrated approach to CDMO services is designed to reduce time to market for complex therapeutic agents while maintaining rigorous quality standards. With a long history in pharmaceutical synthesis and ongoing commitment to expanding its capabilities, HAS continues to adapt to evolving industry demands and sustain its role as a partner for drug developers worldwide.